Arcutis Biotherapeutics vs Aurinia Pharmaceuticals
ARQT and AUPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQT and AUPH compare
Arcutis Biotherapeutics is the larger company, worth 1.7 times as much as Aurinia Pharmaceuticals ($3.6B against $2.1B).
On earnings, Aurinia Pharmaceuticals is cheaper: it trades at 6.9× trailing earnings, against 128× for Arcutis Biotherapeutics.
Arcutis Biotherapeutics grew revenue faster over the last twelve months (60.0% versus 21.0% for Aurinia Pharmaceuticals).
Aurinia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 97.7% compared with 5.9% at Arcutis Biotherapeutics.
Aurinia Pharmaceuticals scores higher on the StockData Score (13 against 11 for Arcutis Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQT | AUPH |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | $2.1B |
| Share price | $28.26 | $15.73 |
| Change, 1 year | 20.5% | 1.2% |
| Change, 5 years | 55.4% | −44.7% |
| Beta (5Y) | 0.92 | 1.06 |
| Employees | 354 | 128 |
| StockData Score | ||
| Total score | 11 | 13 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 4 | 4 |
| Health score | 3 | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 128× | 6.9× (better) |
| P/S | 7.0× | 6.6× (better) |
| P/B | 14.6× | 3.2× (better) |
| EV/EBITDA | 96.7× | 11.7× (better) |
| P/FCF | 59.5× | – |
| FCF yield | 1.7% | – |
| Fair value | $6.04 | $41.31 |
| Margin of safety | −368% | 61.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 60.0% (better) | 21.0% |
| Revenue growth, 5Y average | – | 41.4% |
| Net income growth (TTM) | – | 304% |
| EPS growth (TTM) | – | 309% |
| Profitability | ||
| Gross margin | 91.2% (better) | 90.6% |
| Operating margin | 6.9% | 48.6% (better) |
| Net margin | 5.9% | 97.7% (better) |
| FCF margin | 11.7% | – |
| Return on equity | 14.9% | 61.4% (better) |
| Return on invested capital | 32.9% | 34.6% (better) |
| Financial health | ||
| Debt / equity | 0.45 | – |
| Net debt / EBITDA | −4.27 | – |
| Interest coverage | 2.6× | 40.4× (better) |
| Current ratio | 2.92 | 6.12 (better) |
| Altman Z-score | 6.54 | 8.32 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.6% |
| Shareholder yield | 0.00% | 3.6% (better) |
| Ownership | ||
| Held by institutions | 105% | 58.3% |
| Held by insiders | 9.3% | 17.3% |
| Insider net buying, 12 months | −$11.1M | $24.6M (better) |
| Short interest, % of float | 15.9% | 6.4% |
Go deeper
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
- AUPH stock overview
- AUPH income statement
- AUPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.